SYNTHETIC BLOOD POTENTIAL AS A DRUG DELIVERY SYSTEM
SYNTHETIC BLOOD POTENTIAL AS A DRUG DELIVERY SYSTEM for petroleum-based drugs is noted in a May 7 press release by Synthetic Blood Corp. "The preliminary data indicates synthetic blood can transport many drugs, natrients, and enzyme systems without any significant loss of stability," the release states. "It represents an effective delivery system for the infusion of drugs." According to the release, synthetic blood is a sterile, water-based system consisting of two liquids of different densities which, when properly combined have the physical and chemical properties of human blood. It transports oxygen and when given in transfusion, can maintain or restore normal circulating volume and blood pressure. Metabolized in a similar fashion as natural blood, synthetic blood has the same physiological range and merges with the existing blood system, the company says. The product is envisioned as a potential replacement for human blood in a number of applications and as a direct replacement for blood plasma and volume extenders, the release indicated. The company, Synthetic Blood Corp., is a joint venture between Chicago-based Quixote Corp. and the venture capital arm of Allstate Insurance Company. Perfluorochemical (PFC) emulsions are currently the compounds farthest along in development as blood substitutes. The oxygen transport agent Fluosol-DA, a PFC manufactured by the Green Cross subsidiary Alpha Therapeutics, currently has an NDA as a red blood cell substitute pending. The company reports in the product's patent literature that synthetic blood has a wider range of properties than the oxygen transport agent Fluosol including an ability: to hold oxygen in reserve and release it in accordance with physiological tension; to add or disperse hemoglobin without loss of stability; and to transport nonpolar drug entities and enzyme systems without loss of stability. Synthetic blood does not contain Factor VIII, the clotting agent found in natural blood, but does not interfere with clotting mechanisms of the recipient's blood, the release maintains. Both product and process patents have been issued for the biological product and some limited animal testing has been performed. According to the company, synthetic blood is roughly 3-1/2 years away from clinical trials.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Sign in to continue reading.
Need a specific report?
1000+ reports available
New to Pink Sheet?
Start a free trial today!
Register for our free email digests: